Zhang Xinyan, Feng Jie, Ye Xue, Yao Yu, Zhou Ping, Chen Xiaoxin
Cancer Research Program, Julius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, Durham 27707, USA, and Gynecological Oncology Center, Peking University People's Hospital, Beijing, P. R. China.
Gynecol Oncol. 2006 Dec;103(3):848-52. doi: 10.1016/j.ygyno.2006.05.016. Epub 2006 Jun 23.
The purpose of this study was to develop an immunocytokine for immunotherapy of human ovarian cancer.
The single-chain Fv of a monoclonal antibody, COC183B2, specific for an ovarian carcinoma-associated antigen (OC183B2), was genetically fused with the coding sequence of interleukin 2 (IL-2). The fusion protein, also called immunocytokine, IL-2-183B2scFv, was expressed in CHO cells and examined for its specificity and biological function.
The immunocytokine, IL-2-183B2scFv, retained the functions of both the antibody and IL-2. It was able to target IL-2 to tumor cells that overexpress OC183B2, and stimulate the proliferation of an IL-2-dependent cell line, CTLL-2.
The IL-2-183B2scFv maintains the functions of both IL-2 and antibody. It can be potentially used for immunotherapy of ovarian cancer by delivering a high concentration of IL-2 to OC183B2-expressing ovarian cancer cells.
